Chemomab Therapeutics Ltd. SEC filings CMMB

Chemomab Therapeutics Ltd. has 366 filings in SEC EDGAR's recent list, going back to Nov 7, 2011. Its latest annual report, Form 20-F, was filed on Mar 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on May 11, 2023, covering the quarter ended Mar 31, 2023. The most recent current report (Form 6-K) was filed on Nov 3, 2026. The company's fiscal year ends on December 31.

Form Description Filed Period
20-F Annual report (foreign issuer) Mar 23, 2026 Dec 31, 2025
20-F Annual report (foreign issuer) Apr 4, 2025 Dec 31, 2024
20-F Annual report (foreign issuer) Mar 28, 2024 Dec 31, 2023
ARS Annual report to shareholders Mar 21, 2023 Dec 31, 2022
10-K Annual report Mar 20, 2023 Dec 31, 2022
10-K Annual report Mar 30, 2022 Dec 31, 2021
10-K Annual report Mar 9, 2021 Dec 31, 2020
10-K Annual report Mar 17, 2020 Dec 31, 2019
20-F/A Amended annual report (foreign issuer) Apr 24, 2019 Dec 31, 2018
20-F Annual report (foreign issuer) Mar 25, 2019 Dec 31, 2018
20-F Annual report (foreign issuer) Apr 23, 2013 Dec 31, 2012

Showing 11 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
CMMB (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Israel
Headquarters
Tel Aviv
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1534248
Former names
Anchiano Therapeutics Ltd. (until Mar 17, 2021); BioCancell Ltd. (until Nov 3, 2015)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.